Pilot pharmacoeconomic evaluation of fondaparinux treatment of pulmonary embolism (PE) compared to treatment with unfractionated heparin.

Trial Profile

Pilot pharmacoeconomic evaluation of fondaparinux treatment of pulmonary embolism (PE) compared to treatment with unfractionated heparin.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 29 May 2013

At a glance

  • Drugs Fondaparinux sodium (Primary) ; Heparin
  • Indications Pulmonary embolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2008 Status changed from initiated to withdrawn prior to recruitment according to ClinicalTrials.gov.
    • 15 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top